Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease
about
Animal models of hemophiliaLessons Learned from Animal Models of Inherited Bleeding Disorders.A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach.ARFI ultrasound monitoring of hemorrhage and hemostasis in vivo in canine von Willebrand disease and hemophiliaThe Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion.Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: potential for long-term storage of dried platelets for transfusionLong-term expression of canine FVIIa in hemophilic dogsThe diagnosis, management, and postnatal prevention of intraventricular hemorrhage in the preterm neonate.Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model.Canine hemophilia B resulting from a point mutation with unusual consequencesProtein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B.In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.Preclinical trauma studies of recombinant factor VIIa.Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test - Demonstrated in vitro and ex vivo.Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality.In vivo models of haemophilia - status on current knowledge of clinical phenotypes and therapeutic interventions.Animal models of hemophilia and related bleeding disorders.Successful treatment of canine hemophilia by continuous expression of canine FVIIa.N-/O-glycosylation analysis of human FVIIa produced in the milk of transgenic rabbitsComplications of hemophilia A treatment: factor VIII inhibitors.Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin.Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog.Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.Traumatic coagulopathy--part 2: Resuscitative strategies.Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomesRibavirin-induced intracellular GTP depletion activates transcription elongation in coagulation factor VII gene expression.The influence of coagulation and inflammation research on the improvement of polytrauma care.Poly-N-acetylglucosamine fibers amplify the effectiveness of recombinant factor VIIA on clot formation in hemophilia B canine blood.Characterization of canine coagulation factor VII and its complex formation with tissue factor: canine-human cross-species compatibility.In vivo bypass of hemophilia A coagulation defect by factor XIIa implant.Epitope mapping of human factor IX inhibitor antibodies.Activated factor VII: my story.Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX-deficient patient with an inhibitor.
P2860
Q27012571-03EBE921-26C7-484C-AE32-4EED1BDDA999Q30409863-E56B8C94-597E-4974-A6A6-F88D9C524A77Q30442996-E2E5A5EF-ED6F-4422-B4AF-1D83CE53B0AAQ30443003-B0B090BB-7BBA-44D2-BB72-FE2E006C31A5Q30745198-5046C9F7-5D44-4DFD-97E5-245A8C4EBCD9Q33490246-8842495B-D43D-426B-A8EA-4D72BD9E58B7Q33802667-CFCA68C3-BC99-4C2E-A98B-73B2C08C87ECQ33982533-329C5571-81ED-447A-9B38-3B209DB0D671Q34078730-D4A32774-7A8F-45FC-8E06-7DA5D3A1D915Q34326780-06AE2DF8-7FFA-46CA-9938-A46F70BC87F2Q35006603-27226A2A-9E55-4535-A974-93B504C1CBB8Q35006608-4AE45DAC-322E-42E3-80B5-BB6152A631D6Q35109095-E8A2FE03-8CD2-4569-A73B-95E175C17305Q36284643-B0D013EE-937D-4BD5-A01C-D34CB038E0FEQ36337979-16F51479-3E6B-4413-AB96-60B33A4F83CAQ36532500-3CB17A41-AA3C-498B-8B88-9405CF3A5840Q37056724-90D67AF7-2C83-4B72-A530-E1C3482F1463Q37091290-DDB05E25-DA7B-4175-BCAC-0A76D9F06F02Q37162830-8D43A33B-7E17-4979-A815-986D53BB1692Q37277251-411E5EF6-C7FB-4060-896E-6C6D7118CB06Q37332201-3EB94C98-F182-4D13-AED5-7D38F2E360D5Q37570030-998D7221-8B0D-4C13-8A7B-F00097A2FB0CQ37586365-9D21CDB6-186B-435D-9DE0-09779013FBC7Q37778292-AF5BACB3-1041-45CD-A6F6-E65535C504FCQ38176103-C29A8034-8151-474B-8FDD-77DB7FC48D40Q38235951-22035405-5229-41B5-8CCC-4C4CB1ACC5EAQ39262923-92B2700A-E9FC-47E3-9EA2-3CB3EB16B6E3Q39611127-C89BA542-731A-47AB-AFAA-936B4F466B1EQ42139651-F610BD88-7C46-4429-9DBC-C71C4E05B6EEQ45859525-289C0F87-55AC-4FC2-A590-3379DEDE8C45Q45865821-8BCF17C2-EA72-4B37-BDFB-C32B097723D5Q45866368-102E863E-F35F-4851-8E73-A8465B10A315Q45877085-F1386A92-D2F3-4E82-835B-40541BE483B0Q45881284-3D090363-D603-46BD-B40E-3765F2D477E8
P2860
Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease
description
1989 nî lūn-bûn
@nan
1989 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Effect of recombinant factor V ...... B, and von Willebrand disease
@ast
Effect of recombinant factor V ...... B, and von Willebrand disease
@en
type
label
Effect of recombinant factor V ...... B, and von Willebrand disease
@ast
Effect of recombinant factor V ...... B, and von Willebrand disease
@en
prefLabel
Effect of recombinant factor V ...... B, and von Willebrand disease
@ast
Effect of recombinant factor V ...... B, and von Willebrand disease
@en
P2093
P2860
P921
P356
P1476
Effect of recombinant factor V ...... B, and von Willebrand disease
@en
P2093
P2860
P304
P356
10.1073/PNAS.86.4.1382
P407
P577
1989-02-01T00:00:00Z